- Home
- CUE vs CCEL Comparison
CUE vs CCEL Comparison
Compare CUE & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- CCEL
- Stock Information
- Founded
- CUE 2014
- CCEL 1989
- Country
- CUE United States
- CCEL United States
- Employees
- CUE N/A
- CCEL N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- CCEL Managed Health Care
- Sector
- CUE Health Care
- CCEL Health Care
- Exchange
- CUE Nasdaq
- CCEL Nasdaq
- Market Cap
- CUE 48.0M
- CCEL 39.9M
- IPO Year
- CUE 2018
- CCEL 1997
- Fundamental
- Price
- CUE $0.70
- CCEL $5.13
- Analyst Decision
- CUE Strong Buy
- CCEL Strong Buy
- Analyst Count
- CUE 3
- CCEL 1
- Target Price
- CUE $3.00
- CCEL $8.50
- AVG Volume (30 Days)
- CUE 220.4K
- CCEL 8.3K
- Earning Date
- CUE 08-13-2025
- CCEL 07-14-2025
- Dividend Yield
- CUE N/A
- CCEL 7.80%
- EPS Growth
- CUE N/A
- CCEL N/A
- EPS
- CUE N/A
- CCEL 0.01
- Revenue
- CUE $7,991,000.00
- CCEL $32,102,750.00
- Revenue This Year
- CUE N/A
- CCEL $2.49
- Revenue Next Year
- CUE $23.84
- CCEL $0.95
- P/E Ratio
- CUE N/A
- CCEL $322.13
- Revenue Growth
- CUE 13.83
- CCEL 2.33
- 52 Week Low
- CUE $0.45
- CCEL $4.75
- 52 Week High
- CUE $1.99
- CCEL $9.43
- Technical
- Relative Strength Index (RSI)
- CUE 55.84
- CCEL 50.16
- Support Level
- CUE $0.54
- CCEL $5.00
- Resistance Level
- CUE $0.66
- CCEL $5.31
- Average True Range (ATR)
- CUE 0.06
- CCEL 0.22
- MACD
- CUE 0.01
- CCEL 0.02
- Stochastic Oscillator
- CUE 81.98
- CCEL 43.09
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.